RÉSUMÉ
The prognosis for Cholangiocarcinoma (CCA) is unfavorable, necessitating the development of new therapeutic approach such as magnetic hyperthermia therapy (MHT) which is induced by magnetic nano-particle (MNPs) drug to bridge the treatment gap. Given the deep location of CCA within the abdominal cavity and proximity to vital organs, accurately predict the individualized treatment effects and safety brought by the distribution of MNPs in tumor will be crucial for the advancement of MHT in CCA. The Mimics software was used in this study to conduct three-dimensional reconstruction of abdominal computed tomography (CT) and magnetic reso-nance imaging images from clinical patients, resulting in the generation of a realistic digital geometric model representing the human biliary tract and its adjacent structures. Subsequently, The COMSOL Multiphysics software was utilized for modeling CCA and calculating the heat transfer law resulting from the multi-regional distribution of MNPs in CCA. The temperature within the central region of irregular CCA measured approximately 46°C, and most areas within the tumor displayed temperatures surpassing 41°C. The temperature of the inner edge of CCA is only 39 â¼ 41â, however, it can be ameliorated by adjusting the local drug concentration through simulation system. For CCA with diverse morphologies and anatomical locations, the multi-regional distribution patterns of intratumoral MNPs and a slight overlap of drug distribution areas synergistically enhance intratumoral temperature while ensuring treatment safety. The present study highlights the practicality and imperative of incorporating personalized intratumoral MNPs distribution strategy into clinical practice for MHT, which can be achieved through the development of an integrated simulation system which incorporates medical image data and numerical calculations.
Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Hyperthermie provoquée , Cholangiocarcinome/thérapie , Cholangiocarcinome/imagerie diagnostique , Cholangiocarcinome/traitement médicamenteux , Humains , Hyperthermie provoquée/méthodes , Tumeurs des canaux biliaires/thérapie , Tumeurs des canaux biliaires/imagerie diagnostique , Tumeurs des canaux biliaires/traitement médicamenteux , Simulation numérique , Nanoparticules magnétiques d'oxyde de fer/composition chimique , Modèles biologiquesRÉSUMÉ
BACKGROUND: Mass-forming intrahepatic cholangiocarcinoma (mICC) is the most frequent type of ICC. In contrast-enhanced computed tomography, mICC is visualized as a hypodense lesion with distal dilatation of intrahepatic bile ducts. The presented case illustrates the unusual manifestation of mICC in a 71-year-old male patient, where despite the extensive tumor mass and the hilar infiltration, the dilatation of intrahepatic bile ducts and cholestasis were not noted. METHODS: A literature review on PubMed was performed. Primarily, 547 records were identified, and the titles and abstracts were systematically searched. Regarding the inclusion and exclusion criteria, 31 papers describing the non-cancerous liver lesions mimicking ICC were included in the further analysis. RESULTS: In 41.9% of the analyzed non-cancerous lesions, the obstruction of the bile ducts was not noted, similar to our patient. A significant cholestasis has been found in 30.03% of analyzed patients. The invasion of the liver hilum was noted in one-third of the patients. CONCLUSIONS: Atypical radiological features in lesions suspected of ICC, such as the absence of intrahepatic bile-duct dilation, are common in benign lesions. In the case of radiologically atypical lesions suspected of ICC, the diagnostic imaging needs to be correlated with clinical data, and the diagnosis should be confirmed with a pathological examination.
Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Cholestase , Humains , Cholangiocarcinome/imagerie diagnostique , Mâle , Sujet âgé , Tumeurs des canaux biliaires/imagerie diagnostique , Cholestase/imagerie diagnostique , Tomodensitométrie/méthodes , Diagnostic différentiel , Conduits biliaires intrahépatiques/imagerie diagnostique , Conduits biliaires intrahépatiques/anatomopathologieRÉSUMÉ
Prostate-specific membrane antigen (PSMA) targeted tracers show increased uptake in several malignancies, indicating a potential for peptide radioligand therapy. Intra-arterial injection of radiotracers can increase the therapeutic window. This study aimed to evaluate the feasibility of intra-arterial injection of [68Ga]Ga-PSMA-11 for intrahepatic cholangiocarcinoma and compare tracer uptake after intrahepatic arterial injection and intravenous injection. Three patients with intrahepatic cholangiocarcinoma received [68Ga]Ga-PSMA-11 through a hepatic arterial infusion pump, followed by positron emission tomography/computed tomography (PET/CT). Two-three days later, patients underwent PET/CT after intravenous [68Ga]Ga-PSMA-11 injection. All tumours showed higher uptake on the intra-arterial scan compared with the intravenous scan: the intra-arterial / intravenous standardised uptake value normalised by lean body mass ratios were 1.40, 1.46, and 1.54. Local intra-arterial PSMA injection is possible in patients with intrahepatic cholangiocarcinoma. Local injection increases tumour-to-normal tissue ratios, increasing the therapeutic window for theranostic applications. RELEVANCE STATEMENT: Intra-arterial Prostate specific membrane antigen (PSMA) injection increases the therapeutic window for potential theranostic application in intrahepatic cholangiocarcinoma. KEY POINTS: Three patients with intrahepatic cholangiocarcinoma underwent PET/CT after intra-arterial and intravenous injection of [68Ga]Ga-PSMA-11. Intra-arterial injection showed higher uptake than intravenous injection. PSMA-targeted imaging could be valuable for a subset of intrahepatic cholangiocarcinoma patients.
Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Radio-isotopes du gallium , Tomographie par émission de positons couplée à la tomodensitométrie , Humains , Cholangiocarcinome/imagerie diagnostique , Tomographie par émission de positons couplée à la tomodensitométrie/méthodes , Tumeurs des canaux biliaires/imagerie diagnostique , Tumeurs des canaux biliaires/traitement médicamenteux , Mâle , Adulte d'âge moyen , Sujet âgé , Radio-isotopes du gallium/administration et posologie , Artère hépatique/imagerie diagnostique , Étude de validation de principe , Isotopes du gallium , Injections artérielles , Femelle , Perfusions artérielles , Oligopeptides/administration et posologie , Études de faisabilité , Pompes à perfusion , Radiopharmaceutiques/administration et posologieSujet(s)
Cholangiopancréatographie rétrograde endoscopique , Cholestase , Drainage , Humains , Drainage/méthodes , Cholangiopancréatographie rétrograde endoscopique/méthodes , Cholestase/étiologie , Cholestase/chirurgie , Cholestase/imagerie diagnostique , Cholestase/thérapie , Endoscopie digestive/méthodes , Mâle , Tumeurs des canaux biliaires/complications , Tumeurs des canaux biliaires/imagerie diagnostique , Sujet âgé , FemelleSujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , , Tomodensitométrie , Humains , Tumeurs des canaux biliaires/imagerie diagnostique , Tumeurs des canaux biliaires/mortalité , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/chirurgie , Cholangiocarcinome/imagerie diagnostique , Cholangiocarcinome/mortalité , Cholangiocarcinome/anatomopathologie , Cholangiocarcinome/chirurgie , Pronostic , Taux de survie , Tomodensitométrie/méthodesSujet(s)
Tumeurs des canaux biliaires , Thérapie laser , Humains , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/imagerie diagnostique , Thérapie laser/méthodes , Endoscopie digestive/méthodes , Mâle , Conduits biliaires intrahépatiques/chirurgie , Conduits biliaires intrahépatiques/imagerie diagnostique , Sujet âgé , Femelle , Carcinome papillaire/chirurgie , Carcinome papillaire/imagerie diagnostique , Cholangiopancréatographie rétrograde endoscopique/méthodesRÉSUMÉ
Hepatobiliary mucoepidermoid carcinoma is a rare malignant tumor comprising mucous, intermediate, and epidermoid cells. Herein, we presented a case of primary liver mucoepidermoid carcinoma preoperatively misdiagnosed as conventional intrahepatic cholangiocarcinoma. A 67-year-old male was admitted to our hospital. Preoperative laboratory tests showed increased aspartate transaminase, alanine transaminase, and carbohydrate antigen 19-9. Abdominal Computer Tomography revealed a 4.8 × 4.9 cm liver mass in segment VI. A preliminary diagnosis of intrahepatic cholangiocarcinoma was made, with undergoing partial hepatectomy. However, on histopathology, the tumor comprised a mixture of epidermoid, mucous, and intermediate cells with diffuse infiltrating at the tumor margin. On special stains, mucous and intermedia cells were positive for mucicarmine and Alcian blue, whereas epidermoid cells were positive for Keratin 5/6 and p63. Intermediate cells are also positive for p63. All tumor cells were positive for Keratin 7. The Ki-67 index was 35%. The final diagnosis was primary hepatic mucoepidermoid carcinoma. Although rare, hepatic mucoepidermoid carcinoma should be considered in the intrahepatic cholangiocarcinoma differential diagnosis. We reviewed previous studies and found that hepatobiliary mucoepidermoid carcinoma is more likely to originate from the biliary tract adjacent to the tumor.
Sujet(s)
Carcinome mucoépidermoïde , Tumeurs du foie , Humains , Mâle , Carcinome mucoépidermoïde/anatomopathologie , Carcinome mucoépidermoïde/diagnostic , Carcinome mucoépidermoïde/chirurgie , Carcinome mucoépidermoïde/imagerie diagnostique , Sujet âgé , Tumeurs du foie/anatomopathologie , Tumeurs du foie/diagnostic , Tumeurs du foie/imagerie diagnostique , Tumeurs du foie/chirurgie , Cholangiocarcinome/anatomopathologie , Cholangiocarcinome/diagnostic , Cholangiocarcinome/imagerie diagnostique , Cholangiocarcinome/chirurgie , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/diagnostic , Tumeurs des canaux biliaires/imagerie diagnostique , Tumeurs des canaux biliaires/chirurgie , Diagnostic différentiel , TomodensitométrieSujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Médecine de précision , Humains , Cholangiocarcinome/chirurgie , Cholangiocarcinome/imagerie diagnostique , Cholangiocarcinome/anatomopathologie , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/imagerie diagnostique , Tumeurs des canaux biliaires/anatomopathologie , Pronostic ,RÉSUMÉ
Objective: To explore the magnetic resonance imaging (MRI) features and classification of intraductal papillary neoplasm of the bile duct (IPNB). Methods: Data from 90 patients with intraductal papillary neoplasm of the bile duct confirmed pathologically between June 2010 and January 2023 were retrospectively analyzed. The image analysis included the shape and location of the tumor, whether bile ducts had dilatation and the degree of dilation, whether there was a history of liver disease, whether there was a history of schistosomiasis, whether there was cancerous transformation, whether there were concurrent bile duct stones, whether there was hepatic lobe atrophy, whether there was hilar or abdominal lymph node enlargement, whether there was invasion of the bile duct wall, whether there was invasion of surrounding blood vessels, whether the tumor appears on T1-and T2 weighted imaging (T(1)WI and T(2)WI), whether the diffusion was limited, whether there was concurrent bleeding, enhancement rate, and whether there was abdominal fluid accumulation. Intraductal papillary neoplasms of the bile duct were divided into four types according to the morphological classification standards: type I (local bile duct dilation), type II (cystic), type III (free tumor), and type IV (dilated bile duct). The differences in the clinical and MRI features of the four groups of lesions were analyzed. Statistical analysis was performed with a t-test, an analysis of variance, and an χ(2)-test according to the different data. Results: Among the 90 cases with hepatic IPNB, there were 31 cases of type I, 15 cases of type II, 16 cases of type III, and 28 cases of type IV, 41 cases of liver left lobe, 11 cases of right and left lobe liver span, 7 cases of liver right lobes, 2 cases of liver caudate lobe, and 13 cases of hepatic hilar. There were statistically significant differences between the four groups (Pâ <â 0.05) in terms of age, clinical symptoms, direct bilirubin, γ-glutamyltransferase, whether they were cancerous, whether they were combined with bile duct stones, whether the liver lobes were atrophying, whether there was limited diffusion, intrahepatic bile duct diameter, and common bile duct diameter. However, there were no statistically significant differences among the four groups in gender, location, carbohydrate antigen 19-9, history of liver disease, history of schistosomiasis, carcinoembryonic antigen, alanine aminotransferase, aspartate aminotransferase, total bilirubin, whether hemorrhage was associated, lesion enhancement rate, whether the hilar/retroperitoneal lymph node was enlarged, whether the bile duct wall was invaded, whether blood vessels were invaded, and whether abdominal fluid was accumulated (Pâ >â 0.05). Conclusion: MRI manifestations have certain features for different types of intraductal papillary neoplasm of the bile duct tumors; hence, MRI aids in the diagnosis and differential diagnosis of this disease.
Sujet(s)
Tumeurs des canaux biliaires , Imagerie par résonance magnétique , Humains , Études rétrospectives , Imagerie par résonance magnétique/méthodes , Tumeurs des canaux biliaires/imagerie diagnostique , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/diagnostic , Conduits biliaires intrahépatiques/imagerie diagnostique , Mâle , Femelle , Adulte d'âge moyen , Sujet âgé , AdulteRÉSUMÉ
This study aims to determine the predictive role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) derived radiomic model in tumor immune profiling and immunotherapy for cholangiocarcinoma. To perform radiomic analysis, immune related subgroup clustering was first performed by single sample gene set enrichment analysis (ssGSEA). Second, a total of 806 radiomic features for each phase of DCE-MRI were extracted by utilizing the Python package Pyradiomics. Then, a predictive radiomic signature model was constructed after a three-step features reduction and selection, and receiver operating characteristic (ROC) curve was employed to evaluate the performance of this model. In the end, an independent testing cohort involving cholangiocarcinoma patients with anti-PD-1 Sintilimab treatment after surgery was used to verify the potential application of the established radiomic model in immunotherapy for cholangiocarcinoma. Two distinct immune related subgroups were classified using ssGSEA based on transcriptome sequencing. For radiomic analysis, a total of 10 predictive radiomic features were finally identified to establish a radiomic signature model for immune landscape classification. Regarding to the predictive performance, the mean AUC of ROC curves was 0.80 in the training/validation cohort. For the independent testing cohort, the individual predictive probability by radiomic model and the corresponding immune score derived from ssGSEA was significantly correlated. In conclusion, radiomic signature model based on DCE-MRI was capable of predicting the immune landscape of chalangiocarcinoma. Consequently, a potentially clinical application of this developed radiomic model to guide immunotherapy for cholangiocarcinoma was suggested.
Sujet(s)
Cholangiocarcinome , Immunothérapie , Imagerie par résonance magnétique , Humains , Cholangiocarcinome/imagerie diagnostique , Cholangiocarcinome/immunologie , Cholangiocarcinome/thérapie , Cholangiocarcinome/génétique , Imagerie par résonance magnétique/méthodes , Immunothérapie/méthodes , Mâle , Tumeurs des canaux biliaires/imagerie diagnostique , Tumeurs des canaux biliaires/immunologie , Tumeurs des canaux biliaires/thérapie , Femelle , Adulte d'âge moyen , Produits de contraste , Courbe ROC , Sujet âgé , TranscriptomeSujet(s)
Angiocholite , Cholestase , Drainage , Endosonographie , Échographie interventionnelle , Humains , Angiocholite/étiologie , Angiocholite/chirurgie , Drainage/méthodes , Endosonographie/méthodes , Cholestase/étiologie , Cholestase/chirurgie , Cholestase/imagerie diagnostique , Cholestase/thérapie , Tumeurs des canaux biliaires/complications , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/imagerie diagnostique , Mâle , Sujet âgé , Maladie aigüe , Réintervention/méthodes , Endoprothèses , FemelleRÉSUMÉ
BACKGROUND: For many tumors, radiomics provided a relevant prognostic contribution. This study tested whether the computed tomography (CT)-based textural features of intrahepatic cholangiocarcinoma (ICC) and peritumoral tissue improve the prediction of survival after resection compared with the standard clinical indices. METHODS: All consecutive patients affected by ICC who underwent hepatectomy at six high-volume centers (2009-2019) were considered for the study. The arterial and portal phases of CT performed fewer than 60 days before surgery were analyzed. A manual segmentation of the tumor was performed (Tumor-VOI). A 5-mm volume expansion then was applied to identify the peritumoral tissue (Margin-VOI). RESULTS: The study enrolled 215 patients. After a median follow-up period of 28 months, the overall survival (OS) rate was 57.0%, and the progression-free survival (PFS) rate was 34.9% at 3 years. The clinical predictive model of OS had a C-index of 0.681. The addition of radiomic features led to a progressive improvement of performances (C-index of 0.71, including the portal Tumor-VOI, C-index of 0.752 including the portal Tumor- and Margin-VOI, C-index of 0.764, including all VOIs of the portal and arterial phases). The latter model combined clinical variables (CA19-9 and tumor pattern), tumor indices (density, homogeneity), margin data (kurtosis, compacity, shape), and GLRLM indices. The model had performance equivalent to that of the postoperative clinical model including the pathology data (C-index of 0.765). The same results were observed for PFS. CONCLUSIONS: The radiomics of ICC and peritumoral tissue extracted from preoperative CT improves the prediction of survival. Both the portal and arterial phases should be considered. Radiomic and clinical data are complementary and achieve a preoperative estimation of prognosis equivalent to that achieved in the postoperative setting.
Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Hépatectomie , , Tomodensitométrie , Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/imagerie diagnostique , Tumeurs des canaux biliaires/mortalité , Cholangiocarcinome/chirurgie , Cholangiocarcinome/anatomopathologie , Cholangiocarcinome/imagerie diagnostique , Cholangiocarcinome/mortalité , Études de suivi , Hépatectomie/mortalité , Pronostic , Études rétrospectives , Taux de survie , Tomodensitométrie/méthodesRÉSUMÉ
OBJECTIVES: This study aimed to compare the safety and effectiveness of percutaneous endobiliary radiofrequency ablation with stent placement (RFA group) versus stent placement alone (stent group) in patients with type IV hilar cholangiocarcinoma. METHODS: This prospective nonrandomized study was conducted between October 2021 and April 2023. The study included 56 participants (33 men and 23 women, median age 73 years) who underwent percutaneous endobiliary RFA with stent placement (n = 25) or stent placement alone (n = 31) for type IV hilar cholangiocarcinoma. The primary end point was stent patency, while the secondary end points were procedure-related adverse events (AE) and overall survival. RESULTS: The percutaneous endobiliary RFA and/or stent placement were successfully completed in all patients in both groups. The median stent patency rate was higher in the RFA group than the stent group (188 days vs. 155 days, p = 0.048). There were no differences in AEs (grade 1 [5 in RFA group vs. 5 in stent group, p = 0.74] and grade 2 AEs [2 vs. 4, p = 0.68]) and patients' survival (median 222 days vs. 214 days, p = 0.49) between the two groups. CONCLUSIONS: In patients with type IV hilar cholangiocarcinoma, percutaneous endobiliary RFA with stent placement may improve stent patency without increasing the risk of AEs compared to stent placement alone.
Sujet(s)
Tumeurs des canaux biliaires , Ablation par radiofréquence , Endoprothèses , Humains , Femelle , Mâle , Sujet âgé , Études prospectives , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/imagerie diagnostique , Ablation par radiofréquence/méthodes , Adulte d'âge moyen , Résultat thérapeutique , Tumeur de Klatskin/chirurgie , Sujet âgé de 80 ans ou plusRÉSUMÉ
AIMS: To explore the MRI characteristics and clinical outcome of the "very early" intrahepatic cholangiocarcinoma (iCCA) ≤2.0cm. MATERIALS AND METHODS: Totally 213 pathologically confirmed iCCAs (44 ≤ 2.0cm and 169 of 2.0-5.0cm) from two institutes were included. Forty-four matching non-iCCA malignancies ≤2.0cm were also enrolled. Recurrence-free survival (RFS) was estimated and compared between iCCAs ≤2.0cm and 2.0-5.0cm. MRI features were analyzed and compared between iCCAs ≤2.0cm and 2.0-5.0cm, as well as between iCCAs ≤2.0cm and non-iCCAs ≤2.0cm. Univariate and multivariate regression analyses were performed to identify independent imaging features for discrimination. An MRI-based diagnostic model for iCCA ≤2.0cm was constructed by incorporating the independent imaging features. RESULTS: ICCAs ≤2.0cm had a significantly longer RFS than those of 2.0-5.0cm (log rank P=0.014). Imaging features of homogeneous signal (odds ratio (OR) = 6.677, P<0.001) and lack of vessel invasion (OR=7.56, P<0.001) were more frequently displayed in iCCAs ≤2.0cm compared to iCCAs of 2.0-5.0cm independently. In the small lesions ≤2.0cm, imaging features of progressive or persistent enhancement pattern (OR=27.78, P=0.002) and rim diffusion restriction (OR=5.70, P=0.027) were independent imaging features suggestive of iCCA over non-iCCA malignancy; their combination yielded an area under the curve value of 0.824, with a sensitivity of 97.73%. CONCLUSION: The "very early" iCCA ≤2.0cm was associated with a favorable outcome after surgery, it displayed different and relatively atypical imaging manifestations compared with those of 2.0-5.0cm. Furthermore, in the small lesions ≤ 2.0cm, MRI can be served as a useful non-invasive diagnostic tool for iCCA in clinical screening with high sensitivity.
Sujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Imagerie par résonance magnétique , Humains , Cholangiocarcinome/imagerie diagnostique , Tumeurs des canaux biliaires/imagerie diagnostique , Tumeurs des canaux biliaires/anatomopathologie , Mâle , Femelle , Imagerie par résonance magnétique/méthodes , Adulte d'âge moyen , Pronostic , Sujet âgé , Études rétrospectives , AdulteSujet(s)
Cholédocostomie , Endosonographie , Humains , Tumeurs des canaux biliaires/complications , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/imagerie diagnostique , Cholédocostomie/méthodes , Cholestase/chirurgie , Cholestase/étiologie , Cholestase/imagerie diagnostique , Endosonographie/méthodes , Échographie interventionnelle/méthodesRÉSUMÉ
A 74-year-old man with obstructive jaundice presented with a thickened distal bile duct wall. A transpapillary forceps biopsy revealed an adenocarcinoma; however, because the tumor image was different from that of a typical cholangiocarcinoma, endoscopic ultrasound-guided fine-needle aspiration was performed on the tumor and enlarged lymph nodes. The tumor cells were positive for synaptophysin and CD56 with a Ki67 labeling index of 95%, and he was diagnosed with small cell neuroendocrine carcinoma. We diagnosed a bile duct tumor with neuroendocrine carcinoma component with lymph node metastasis. Preoperative chemotherapy for neuroendocrine carcinoma was administered because R0 resection was difficult and the risk of postoperative recurrence was high. Three courses of chemotherapy with carboplatin and etoposide resulted in marked tumor shrinkage, and radical resection was performed 3 months after diagnosis. Postoperative pathology revealed adenocarcinoma in the mucosal epithelium and small cell neuroendocrine carcinoma in the submucosa, most of which resolved with chemotherapy. Carboplatin and etoposide were resumed as adjuvant chemotherapy, and 67 months of recurrence-free survival were achieved after surgery.
Sujet(s)
Tumeurs des canaux biliaires , Carcinome neuroendocrine , Traitement néoadjuvant , Humains , Mâle , Sujet âgé , Tumeurs des canaux biliaires/traitement médicamenteux , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/imagerie diagnostique , Carcinome neuroendocrine/traitement médicamenteux , Carcinome neuroendocrine/anatomopathologie , Carcinome neuroendocrine/imagerie diagnostique , Carcinome neuroendocrine/chirurgie , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Étoposide/administration et posologie , Étoposide/usage thérapeutique , Carboplatine/administration et posologie , Carboplatine/usage thérapeutique , Pronostic , Traitement médicamenteux adjuvant , Adénocarcinome/traitement médicamenteux , Adénocarcinome/anatomopathologie , Métastase lymphatiqueSujet(s)
Tumeurs des canaux biliaires , Cholangiocarcinome , Veines hépatiques , Veine porte , Humains , Cholangiocarcinome/imagerie diagnostique , Veine porte/imagerie diagnostique , Tumeurs des canaux biliaires/anatomopathologie , Tumeurs des canaux biliaires/imagerie diagnostique , Tumeurs des canaux biliaires/chirurgie , Tumeurs des canaux biliaires/complications , Veines hépatiques/imagerie diagnostique , Fistule artérioveineuse/imagerie diagnostique , Fistule artérioveineuse/étiologie , Fistule artérioveineuse/complications , Fistule artérioveineuse/chirurgie , Lithiase/chirurgie , Lithiase/imagerie diagnostique , Lithiase/complications , Mâle , Adulte d'âge moyen , Maladies du foie/imagerie diagnostique , Maladies du foie/diagnostic , Maladies du foie/étiologie , Diagnostic différentiel , Femelle , Tomodensitométrie , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: The benefits of regular surveillance imaging for cholangiocarcinoma in patients with primary sclerosing cholangitis (PSC) are unclear. Hence, we aimed to evaluate the impact of regular magnetic resonance cholangiopancreatography (MRCP) on outcomes of patients with PSC in Australia, where the practice of MRCP surveillance is variable. METHODS: The relationship between MRCP surveillance and survival outcomes was assessed in a multicenter, retrospective cohort of patients with PSC from 9 tertiary liver centers in Australia. An inverse probability of treatment weighting approach was used to balance groups across potentially confounding covariates. RESULTS: A total of 298 patients with PSC with 2117 person-years of follow-up were included. Two hundred and twenty patients (73.8%) had undergone MRCP surveillance. Regular surveillance was associated with a 71% reduced risk of death on multivariate weighted Cox analysis (HR: 0.29, 95% CI: 0.14-0.59, p < 0.001) and increased likelihood of having earlier endoscopic retrograde cholangiopancreatography from the date of PSC diagnosis in patients with a dominant stricture (p < 0.001). However, survival posthepatobiliary cancer diagnosis was not significantly different between both groups (p = 0.74). Patients who had surveillance of less than 1 scan a year (n = 41) had comparable survival (HR: 0.46, 95% CI 0.16-1.35, p = 0.16) compared to patients who had surveillance at least yearly (n = 172). CONCLUSIONS: In this multicenter cohort study that employed inverse probability of treatment weighting to minimize selection bias, regular MRCP was associated with improved overall survival in patients with PSC; however, there was no difference in survival after hepatobiliary cancer diagnosis. Further prospective studies are needed to confirm the benefits of regular MRCP and optimal imaging interval in patients with PSC.
Sujet(s)
Cholangiocarcinome , Cholangiopancréatographie par résonance magnétique , Angiocholite sclérosante , Humains , Angiocholite sclérosante/mortalité , Angiocholite sclérosante/complications , Angiocholite sclérosante/imagerie diagnostique , Mâle , Femelle , Études rétrospectives , Adulte d'âge moyen , Australie/épidémiologie , Adulte , Cholangiocarcinome/mortalité , Cholangiocarcinome/imagerie diagnostique , Tumeurs des canaux biliaires/mortalité , Tumeurs des canaux biliaires/imagerie diagnostique , Sujet âgéRÉSUMÉ
PURPOSE: This study was conducted to investigate the effectiveness of strain elastography in guiding precise and sufficient tissue sampling for perihilar cholangiocarcinoma (CCA) biopsies. METHODS: Our retrospective analysis included 23 liver biopsies conducted between March 2019 and July 2022 for suspected perihilar CCA. An experienced radiologist performed the biopsies via an ultrasound machine with elastography configuration. Tissue stiffness color maps were used for guiding when the biopsies were performed. Strain index value calculations were made by radiologists on recorded images. RESULTS: Patient demographics revealed a mean age of 65.17 ± 9.25 years, with a gender distribution of six females and 17 males. Gray-scale examinations unveiled diverse echogenic characteristics in liver lesions. Elastography-guided biopsies demonstrated no need for repeats, while gray-scale biopsies necessitated re-biopsy in four patients, resulting in cholangiocarcinoma diagnosis (P = 0.037). Strain index values showcased strong inter- and intra-observer agreements (P < 0.001). Notably, no post-biopsy complications emerged in either study group. CONCLUSION: The diagnostic advantage of elastography, particularly in enhancing accuracy in challenging isoechoic lesions, was demonstrated, although the substantial overlap between strain index values of benign and malignant liver masses limits clinical usefulness of this technique.
Sujet(s)
Tumeurs des canaux biliaires , Imagerie d'élasticité tissulaire , Tumeur de Klatskin , Humains , Imagerie d'élasticité tissulaire/méthodes , Mâle , Femelle , Études rétrospectives , Sujet âgé , Tumeurs des canaux biliaires/imagerie diagnostique , Tumeurs des canaux biliaires/anatomopathologie , Adulte d'âge moyen , Tumeur de Klatskin/imagerie diagnostique , Tumeur de Klatskin/anatomopathologie , Biopsie guidée par l'imageRÉSUMÉ
Caroli's disease is also known as Congenital intrahepatic bile duct dilatation, and previously known as a congenital intrahepatic bile duct cyst; it is characterized by single or multiple intrahepatic cystic dilatations. In this article, we report a case of Caroli's disease (CT size 21.2 × 16.9 × 19.8 cm). Preoperative abdominal ultrasound and enhanced CT were misdiagnosed as biliary cystadenoma or hepatic echinococcosis, and finally diagnosed as Caroli's disease by postoperative histopathological examinations. Most of the disease is single or multiple cystic dilatation of small bile duct. Giant Caroli disease, cystic dilations with diameter >20 cm is very rarely seen in the clinic. The lack of experience of diagnosing giant cystic dilatation makes it difficult to make accurate diagnosis. Therefore, we analyze the causes of imaging misdiagnosis through this case report, and summarize the imaging diagnostic skills of the disease combined with relevant imaging diagnosis experience. The purpose of this study is to deepen the understanding of giant Caroli disease among imaging doctors so as to reduce the misdiagnosis of the disease in the future.